vonoprazan 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 4993 | 881681-00-1 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
a potassium-competitive proton pump blocker for the treatment of acid-related disorders. Its potential to combat cytokine release syndrome (CRS) in patients with severely ill COVID-19 was investigated. Accordingly, it is recommended to use tocilizumabin combination with dexamethasone (or another corticosteroid at an equivalent dose) in certain hospitalized patients who are exhibiting rapid respiratory decompensation caused by COVID-19.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 26, 2014 | PMDA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Hepatic function abnormal | 72.93 | 28.42 | 31 | 1726 | 32650 | 50570717 |
| Platelet count decreased | 68.84 | 28.42 | 43 | 1714 | 100683 | 50502684 |
| Decreased appetite | 42.55 | 28.42 | 43 | 1714 | 200880 | 50402487 |
| Anaemia | 36.11 | 28.42 | 44 | 1713 | 252412 | 50350955 |
| Cardiac failure | 33.99 | 28.42 | 25 | 1732 | 76015 | 50527352 |
| Interstitial lung disease | 29.59 | 28.42 | 20 | 1737 | 53156 | 50550211 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Interstitial lung disease | 105.47 | 25.22 | 60 | 2055 | 57658 | 29514754 |
| Hepatic function abnormal | 64.10 | 25.22 | 38 | 2077 | 39221 | 29533191 |
| Oesophagitis | 37.82 | 25.22 | 18 | 2097 | 11905 | 29560507 |
| Renal impairment | 35.66 | 25.22 | 36 | 2079 | 81297 | 29491115 |
| Radiation pneumonitis | 31.57 | 25.22 | 10 | 2105 | 2219 | 29570193 |
| Cerebral infarction | 30.40 | 25.22 | 20 | 2095 | 24655 | 29547757 |
| Adrenal insufficiency | 29.91 | 25.22 | 15 | 2100 | 11099 | 29561313 |
| Cardiac failure | 29.21 | 25.22 | 32 | 2083 | 79255 | 29493157 |
| Cholangitis acute | 27.56 | 25.22 | 7 | 2108 | 702 | 29571710 |
| Immune-mediated enterocolitis | 25.85 | 25.22 | 8 | 2107 | 1645 | 29570767 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Interstitial lung disease | 127.28 | 23.27 | 79 | 4104 | 97653 | 64396896 |
| Hepatic function abnormal | 120.89 | 23.27 | 66 | 4117 | 64247 | 64430302 |
| Platelet count decreased | 69.76 | 23.27 | 69 | 4114 | 167642 | 64326907 |
| Cardiac failure | 57.88 | 23.27 | 56 | 4127 | 132317 | 64362232 |
| Decreased appetite | 55.48 | 23.27 | 79 | 4104 | 281210 | 64213339 |
| Renal impairment | 53.24 | 23.27 | 54 | 4129 | 134963 | 64359586 |
| Cerebral infarction | 47.86 | 23.27 | 31 | 4152 | 41013 | 64453536 |
| Neutrophil count decreased | 38.18 | 23.27 | 35 | 4148 | 77161 | 64417388 |
| Hypergastrinaemia | 37.79 | 23.27 | 7 | 4176 | 173 | 64494376 |
| Enterocolitis | 36.21 | 23.27 | 17 | 4166 | 12001 | 64482548 |
| Pneumonia aspiration | 35.57 | 23.27 | 30 | 4153 | 59241 | 64435308 |
| Anaemia | 33.60 | 23.27 | 75 | 4108 | 378605 | 64115944 |
| Immune-mediated enterocolitis | 30.80 | 23.27 | 10 | 4173 | 2646 | 64491903 |
| Pneumonia bacterial | 29.77 | 23.27 | 16 | 4167 | 15019 | 64479530 |
| Adrenal insufficiency | 28.73 | 23.27 | 18 | 4165 | 22469 | 64472080 |
| Radiation pneumonitis | 28.59 | 23.27 | 10 | 4173 | 3318 | 64491231 |
| Oesophagitis | 26.84 | 23.27 | 17 | 4166 | 21613 | 64472936 |
| Marasmus | 26.82 | 23.27 | 7 | 4176 | 861 | 64493688 |
| Liver disorder | 25.99 | 23.27 | 24 | 4159 | 53327 | 64441222 |
| Cholangitis | 25.69 | 23.27 | 13 | 4170 | 10789 | 64483760 |
| Malignant neoplasm progression | 25.62 | 23.27 | 34 | 4149 | 112837 | 64381712 |
| Myelosuppression | 25.34 | 23.27 | 17 | 4166 | 23813 | 64470736 |
| Enterocolitis haemorrhagic | 25.19 | 23.27 | 8 | 4175 | 1972 | 64492577 |
| Disseminated intravascular coagulation | 25.00 | 23.27 | 19 | 4164 | 32329 | 64462220 |
| Cholangitis acute | 24.20 | 23.27 | 7 | 4176 | 1261 | 64493288 |
| KL-6 increased | 23.75 | 23.27 | 4 | 4179 | 56 | 64494493 |
| Erythema multiforme | 23.73 | 23.27 | 14 | 4169 | 15687 | 64478862 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A02BC08 | ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) Proton pump inhibitors |
| ATC | A02BD14 | ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) Combinations for eradication of Helicobacter pylori |
| ATC | A02BD15 | ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) Combinations for eradication of Helicobacter pylori |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Duodenal ulcer disease | indication | 51868009 | DOID:1724 |
| Gastro-esophageal reflux disease with esophagitis | indication | 266433003 | |
| Gastric ulcer | indication | 397825006 | DOID:10808 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 9.09 | Basic |
| pKa2 | 2.72 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 500MG;500MG;EQ 20MG BASE | VOQUEZNA TRIPLE PAK | PHATHOM | N215152 | May 3, 2022 | RX | CAPSULE, TABLET, TABLET | ORAL | May 3, 2027 | NEW CHEMICAL ENTITY |
| 500MG;EQ 20MG BASE | VOQUEZNA DUAL PAK | PHATHOM | N215153 | May 3, 2022 | RX | CAPSULE, TABLET | ORAL | May 3, 2027 | NEW CHEMICAL ENTITY |
| 500MG;500MG;EQ 20MG BASE | VOQUEZNA TRIPLE PAK | PHATHOM | N215152 | May 3, 2022 | RX | CAPSULE, TABLET, TABLET | ORAL | May 3, 2032 | GENERATING ANTIBIOTIC INCENTIVES NOW |
| 500MG;EQ 20MG BASE | VOQUEZNA DUAL PAK | PHATHOM | N215153 | May 3, 2022 | RX | CAPSULE, TABLET | ORAL | May 3, 2032 | GENERATING ANTIBIOTIC INCENTIVES NOW |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Potassium-transporting ATPase | Transporter | INHIBITOR | Ki | 8 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE |
External reference:
| ID | Source |
|---|---|
| 1R5L3J156G | UNII |
| D10466 | KEGG_DRUG |
| 881681-01-2 | SECONDARY_CAS_RN |
| C4080009 | UMLSCUI |
| CHEBI:136048 | CHEBI |
| HKT | PDB_CHEM_ID |
| CHEMBL2079130 | ChEMBL_ID |
| 15981397 | PUBCHEM_CID |
| DB11739 | DRUGBANK_ID |
| CHEMBL2064032 | ChEMBL_ID |
| 9535 | INN_ID |
| C552956 | MESH_SUPPLEMENTAL_RECORD_UI |
| 11549 | IUPHAR_LIGAND_ID |
Pharmaceutical products:
None